Quote:

---

Sounds like it’s a potential immunomodulator

---

Seladelpar increases the efficiency of fat metabolization. Large fat stores increase inflammatory chemokines. By reducing the amount of fat seladelpar decreases those inflammatory chemokines. It is not a direct immunomodulator so not as effective as leronlimab but it has shown promise. The NASH and PBC trials that were done five years ago were shut down by the company five years ago due to increased liver damage.